BVF Inc. IL Buys 910,747 Shares of Molecular Partners AG (NASDAQ:MOLN)

BVF Inc. IL grew its position in shares of Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,353,968 shares of the company’s stock after buying an additional 910,747 shares during the quarter. BVF Inc. IL’s holdings in Molecular Partners were worth $6,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Analysts Set New Price Targets

Separately, Lifesci Capital began coverage on Molecular Partners in a research report on Tuesday, March 11th. They set an “outperform” rating and a $12.00 price objective for the company.

Molecular Partners Stock Up 8.8 %

Shares of NASDAQ:MOLN opened at $4.08 on Friday. The stock has a market capitalization of $164.73 million, a PE ratio of -1.90 and a beta of 1.16. The firm’s 50 day moving average price is $4.11 and its 200-day moving average price is $4.97. Molecular Partners AG has a twelve month low of $3.36 and a twelve month high of $12.70.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. Analysts expect that Molecular Partners AG will post -1.93 earnings per share for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.